Question explored with the scientific record
Can you please tell me about the benefits of taking medical grade canibis for nerve pain and for sleep also?
For nerve pain, a specific cannabis spray beat placebo in short trials. For sleep, the evidence is thinner and mostly comes from the same pain trials.
The best evidence here is a specific product, Sativex, a mouth spray with equal THC and CBD. In a 5-week randomized, double-blind, placebo-controlled trial of 125 people with peripheral nerve pain, it improved pain intensity (p=0.004), the composite nerve pain score (p=0.007), and sleep (p=0.001) [1]. In MS patients with central nerve pain, it beat placebo on pain (p=0.005) and sleep (p=0.003) over 4 weeks [1]. Those are real, randomized results, not anecdotes. But they are short trials of one product, and the review reporting them is a narrative summary, not an independent meta-analysis [1].
| Outcome | Sativex vs placebo | Trial length |
|---|---|---|
| Peripheral nerve pain intensity | p=0.004 | 5 weeks |
| Nerve pain composite score | p=0.007 | 5 weeks |
| Sleep score (peripheral pain) | p=0.001 | 5 weeks |
| MS central pain | p=0.005 | 4 weeks |
| Sleep (MS central pain) | p=0.003 | 4 weeks |
The sleep case is weaker than the pain case. Most sleep benefit shows up as a side effect of pain relief, not as a sleep treatment tested on its own [1]. A separate review notes CBD increased total sleep time in Parkinson's patients at 160 mg/day, but that is a small, isolated finding [2]. The real-world data is uncontrolled: a 24-week Canadian cohort of 276 people improved on pain and sleep, but nearly half dropped out and there was no control group [4]. An observational study of 47 people on medical cannabis also reported better sleep scores, again with no placebo arm [3].
What this retrieval cannot see: long-term safety, dependence, and head-to-head comparisons against standard nerve pain drugs. Those gaps are real. The short trials also used a pharmaceutical spray, not dispensary flower or edibles, so the doses and ratios do not transfer.
My call: worth a careful trial for nerve pain if standard options have failed, with modest expectations and a clinician watching; for sleep alone, the evidence is too thin to justify it as a first choice. Confidence: moderate for nerve pain, low for sleep.
Sources used 4
-
Therapeutic potential of cannabinoid medicines
This narrative review argues that pharmaceutical cannabinoid medicines, particularly Sativex (THC:CBD oromucosal spray), show established efficacy in multiple sclerosis spasticity and neuropathic pain, with emerging evidence in other indications.
DOI: 10.1002/dta.1529 -
Cannabidiol in medical marijuana: Research vistas and potential opportunities
This paper reviews the pharmacological effects of cannabidiol (CBD) in medical marijuana, highlighting its potential therapeutic benefits for anxiety, mood disorders, and sleep complaints, while contrasting its effects with those of delta-9-tetrahydrocannabinol (THC).
DOI: 10.1016/j.phrs.2017.05.005 -
Clinical and psychosocial changes in adults with opioid use disorder and chronic pain using medical cannabis: a brief report
An observational brief report examining 3-month outcomes after initiating medical cannabis in adults with opioid use disorder and chronic pain who were on buprenorphine/naloxone, finding reduced pain and improved sleep and quality of life but no significant change in illicit opi…
DOI: 10.1186/s42238-025-00297-5 -
Canadian real-world evidence: observational 24-week outcomes for health care practitioner authorized cannabis
Real-world authorization-based medical cannabis use among Canadian adults in a multicenter cohort yielded improvements in pain interference, pain intensity, anxiety, depression, sleep distribution, and quality of life over 24 weeks, with the largest gains in the first 6 weeks bu…
DOI: 10.1080/24740527.2025.2593253